Manidipino Vir

Manidipine Dihydrochloride, the active ingredient in Manidipino Vir, is a dihydropyridine calcium channel blocker presented as an oral tablet for oral use. It is indicated for the treatment of hypertension in adult patients. GNH USA supplies Manidipino Vir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manidipine Dihydrochloride is used to manage high blood pressure, a condition within the cardiovascular disease spectrum. - Primary hypertension: lowers systolic and diastolic pressure through arterial vasodilation. - Secondary hypertension: assists in blood‑pressure control when caused by other disorders. - Isolated systolic hypertension: reduces elevated systolic readings in older adults.

Manidipine Dihydrochloride may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: especially upon standing. - Tachycardia: increased heart rate. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing faintness. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, pruritus, or angioedema. - Myocardial infarction: rare occurrence in susceptible patients. - Atrioventricular block: conduction disturbances. - Renal impairment: worsening kidney function in predisposed individuals.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks. - Blood pressure monitoring: assess baseline and periodic readings. - Cardiovascular history: review for heart failure or recent myocardial infarction. - Liver function: check enzymes in patients with hepatic disease. - Renal function: evaluate creatinine clearance in those with kidney impairment. - Concomitant antihypertensives: adjust doses to avoid excessive hypotension. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and direct sunlight.

Manidipine Dihydrochloride can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations. - Simultaneous use with other potent vasodilators (e.g., nitroglycerin): risk of severe hypotension. - Grapefruit juice: can elevate drug levels leading to toxicity.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance antihypertensive effect, requiring dose adjustment. - Beta‑blockers: additive blood‑pressure lowering effect. - Antidiabetic agents: possible enhancement of hypoglycaemia. - NSAIDs: may blunt antihypertensive response.